CytomX Therapeutics, Inc. (FRA:6C1)
Germany
· Delayed Price · Currency is EUR 3.444
+0.070 (2.07%)
At close: Dec 5, 2025
CytomX Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 113.63 | 138.1 | 101.21 | 53.16 | 37.31 | 68.43 | Upgrade
|
| Revenue Growth (YoY) | -10.26% | 36.45% | 90.38% | 42.48% | -45.47% | 154.36% | Upgrade
|
| Gross Profit | 113.63 | 138.1 | 101.21 | 53.16 | 37.31 | 68.43 | Upgrade
|
| Selling, General & Admin | 28.1 | 29.73 | 30.02 | 40.45 | 39.16 | 36.03 | Upgrade
|
| Research & Development | 62.28 | 83.38 | 77.68 | 106.55 | 114.19 | 112.94 | Upgrade
|
| Operating Expenses | 90.38 | 113.11 | 107.7 | 147 | 153.35 | 148.97 | Upgrade
|
| Operating Income | 23.25 | 25 | -6.48 | -93.84 | -116.04 | -80.54 | Upgrade
|
| Interest & Investment Income | 5 | 7.14 | 9.84 | 1.68 | 0.26 | 1.84 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | -0.04 | -0.03 | 0.34 | -0.08 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | 28.26 | 32.09 | 3.32 | -91.82 | -115.87 | -78.73 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -7.5 | - | - | Upgrade
|
| Pretax Income | 28.26 | 32.09 | 3.32 | -99.32 | -115.87 | -78.73 | Upgrade
|
| Income Tax Expense | 0.25 | 0.22 | 3.89 | - | - | -13.91 | Upgrade
|
| Net Income | 28.02 | 31.87 | -0.57 | -99.32 | -115.87 | -64.82 | Upgrade
|
| Net Income to Common | 28.02 | 31.87 | -0.57 | -99.32 | -115.87 | -64.82 | Upgrade
|
| Shares Outstanding (Basic) | 117 | 84 | 74 | 66 | 64 | 46 | Upgrade
|
| Shares Outstanding (Diluted) | 118 | 85 | 74 | 66 | 64 | 46 | Upgrade
|
| Shares Change (YoY) | 41.04% | 14.82% | 12.27% | 2.48% | 39.01% | 1.79% | Upgrade
|
| EPS (Basic) | 0.24 | 0.38 | -0.01 | -1.51 | -1.81 | -1.40 | Upgrade
|
| EPS (Diluted) | 0.24 | 0.38 | -0.01 | -1.51 | -1.81 | -1.40 | Upgrade
|
| Free Cash Flow | -72.35 | -86.54 | -56.88 | -112.53 | -120.64 | 2.95 | Upgrade
|
| Free Cash Flow Per Share | -0.61 | -1.02 | -0.77 | -1.71 | -1.88 | 0.06 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 20.46% | 18.10% | -6.41% | -176.50% | -311.00% | -117.70% | Upgrade
|
| Profit Margin | 24.66% | 23.08% | -0.56% | -186.82% | -310.54% | -94.73% | Upgrade
|
| Free Cash Flow Margin | -63.67% | -62.66% | -56.19% | -211.67% | -323.33% | 4.31% | Upgrade
|
| EBITDA | 24.53 | 26.76 | -4.31 | -91.39 | -113.34 | -77.97 | Upgrade
|
| EBITDA Margin | 21.58% | 19.38% | -4.26% | -171.91% | - | -113.94% | Upgrade
|
| D&A For EBITDA | 1.28 | 1.77 | 2.18 | 2.44 | 2.71 | 2.57 | Upgrade
|
| EBIT | 23.25 | 25 | -6.48 | -93.84 | -116.04 | -80.54 | Upgrade
|
| EBIT Margin | 20.46% | 18.10% | -6.41% | -176.50% | - | -117.70% | Upgrade
|
| Effective Tax Rate | 0.87% | 0.70% | 117.12% | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.